Cure8 research brief
Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.
Researchers studying IBD biomarkers or lipidomics, clinicians interested in non-invasive diagnostic tests for IBD, and patients or advocates following biomarker research.
Researchers analyzed 719 fecal lipids from 65 treated IBD patients and used machine-learning models to identify lipid signatures that distinguish UC from CD. Lipid classes highlighted included FAHFAs, triglycerides (TGs), ether-linked diacylglycerols (DG(O-)), and ceramides, with modelling achieving AUCs ≥ 0.80 for some comparisons.
The study did not find significant fecal lipidome differences associated with disease activity, fecal calprotectin levels, or BMI in this cohort, and the authors link altered lipid-related gene functions between UC and CD to sphingolipid and ether lipid metabolism pathways.
Results are from an exploratory study using rapid untargeted lipidomics on 65 treated patients and are based on the article abstract; external validation and larger studies are needed before clinical implementation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.
